News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
731,997 Results
Type
Article (44938)
Company Profile (309)
Press Release (686748)
Multimedia
Podcasts (101)
Webinars (14)
Section
Business (212611)
Career Advice (2212)
Deals (37153)
Drug Delivery (119)
Drug Development (84481)
Employer Resources (177)
FDA (16823)
Job Trends (15617)
News (360664)
Policy (34610)
Tag
Academia (2647)
Accelerated approval (8)
Adcomms (32)
Allergies (99)
Alliances (52231)
ALS (108)
Alzheimer's disease (1461)
Antibody-drug conjugate (ADC) (177)
Approvals (16792)
Artificial intelligence (321)
Autoimmune disease (32)
Automation (18)
Bankruptcy (379)
Best Places to Work (11848)
BIOSECURE Act (21)
Biosimilars (123)
Biotechnology (193)
Bladder cancer (94)
Brain cancer (34)
Breast cancer (363)
Cancer (2841)
Cardiovascular disease (226)
Career advice (1844)
Career pathing (33)
CAR-T (189)
CDC (33)
Cell therapy (506)
Cervical cancer (23)
Clinical research (69222)
Collaboration (1016)
Company closure (3)
Compensation (652)
Complete response letters (29)
COVID-19 (2722)
CRISPR (62)
C-suite (306)
Cystic fibrosis (113)
Data (2838)
Decentralized trials (2)
Denatured (31)
Depression (58)
Diabetes (325)
Diagnostics (6533)
Digital health (22)
Diversity (9)
Diversity, equity & inclusion (46)
Drug discovery (137)
Drug pricing (143)
Drug shortages (33)
Duchenne muscular dystrophy (122)
Earnings (89561)
Editorial (44)
Employer branding (21)
Employer resources (153)
Events (117849)
Executive appointments (859)
FDA (18393)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (910)
Gene editing (138)
Generative AI (26)
Gene therapy (392)
GLP-1 (858)
Government (4704)
Grass and pollen (5)
Guidances (180)
Healthcare (19213)
Huntington's disease (31)
IgA nephropathy (39)
Immunology and inflammation (164)
Immuno-oncology (8)
Indications (38)
Infectious disease (2894)
Inflammatory bowel disease (156)
Inflation Reduction Act (9)
Influenza (56)
Intellectual property (117)
Interviews (348)
IPO (17026)
IRA (51)
Job creations (4172)
Job search strategy (1572)
Kidney cancer (14)
Labor market (50)
Layoffs (542)
Leadership (23)
Legal (8581)
Liver cancer (79)
Lung cancer (404)
Lymphoma (198)
Machine learning (9)
Management (61)
Manufacturing (393)
MASH (90)
Medical device (13578)
Medtech (13583)
Mergers & acquisitions (20805)
Metabolic disorders (859)
Multiple sclerosis (100)
NASH (22)
Neurodegenerative disease (126)
Neuropsychiatric disorders (37)
Neuroscience (2148)
NextGen: Class of 2025 (6741)
Non-profit (4574)
Now hiring (46)
Obesity (456)
Opinion (262)
Ovarian cancer (97)
Pain (114)
Pancreatic cancer (112)
Parkinson's disease (187)
Partnered (22)
Patents (294)
Patient recruitment (141)
Peanut (53)
People (60155)
Pharmaceutical (98)
Pharmacy benefit managers (24)
Phase I (21570)
Phase II (30406)
Phase III (22795)
Pipeline (1602)
Policy (214)
Postmarket research (2686)
Preclinical (9132)
Press Release (68)
Prostate cancer (136)
Psychedelics (34)
Radiopharmaceuticals (261)
Rare diseases (481)
Real estate (6380)
Recruiting (67)
Regulatory (23794)
Reports (50)
Research institute (2406)
Resumes & cover letters (373)
Rett syndrome (9)
RNA editing (9)
RSV (53)
Schizophrenia (90)
Series A (156)
Series B (102)
Service/supplier (14)
Sickle cell disease (62)
Special edition (21)
Spinal muscular atrophy (155)
Sponsored (34)
Startups (3808)
State (2)
Stomach cancer (16)
Supply chain (78)
Tariffs (63)
The Weekly (68)
Vaccines (815)
Venture capital (52)
Weight loss (305)
Women's health (44)
Worklife (18)
Date
Today (46)
Last 7 days (470)
Last 30 days (2498)
Last 365 days (32427)
2025 (15823)
2024 (36248)
2023 (41042)
2022 (52163)
2021 (56724)
2020 (55153)
2019 (47880)
2018 (36176)
2017 (33593)
2016 (33212)
2015 (39050)
2014 (32987)
2013 (28119)
2012 (30202)
2011 (30908)
2010 (28913)
Location
Africa (821)
Alabama (60)
Alaska (7)
Arizona (251)
Arkansas (14)
Asia (42051)
Australia (6669)
California (7224)
Canada (2283)
China (669)
Colorado (308)
Connecticut (312)
Delaware (186)
Europe (90326)
Florida (1094)
Georgia (242)
Idaho (58)
Illinois (633)
India (27)
Indiana (364)
Iowa (16)
Japan (217)
Kansas (108)
Kentucky (27)
Louisiana (13)
Maine (64)
Maryland (1017)
Massachusetts (5423)
Michigan (243)
Minnesota (439)
Mississippi (3)
Missouri (85)
Montana (28)
Nebraska (25)
Nevada (78)
New Hampshire (66)
New Jersey (2018)
New Mexico (31)
New York (2035)
North Carolina (1108)
North Dakota (8)
Northern California (3170)
Ohio (230)
Oklahoma (15)
Oregon (40)
Pennsylvania (1573)
Puerto Rico (18)
Rhode Island (36)
South America (1191)
South Carolina (34)
South Dakota (1)
Southern California (2687)
Tennessee (121)
Texas (1081)
United States (27008)
Utah (217)
Virginia (186)
Washington D.C. (73)
Washington State (616)
West Virginia (4)
Wisconsin (66)
731,997 Results for "tris pharma inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Tris Pharma to Unveil Positive Phase 3 Results including a Strong Safety Profile Showcasing the Potential of Cebranopadol, an Investigational First-in-Class Dual-NMR Agonist for the Treatment of Pain, at the 2025 ASRA Annual Meeting
May 1, 2025
·
5 min read
Press Releases
Tris Pharma to Debut Positive Results of Intranasal (Snorting) Human Abuse Potential Study of Cebranopadol, an Investigational First-In-Class Oral Dual-NMR Agonist for the Treatment of Moderate-to-Severe Pain, at the 2025 CPDD Annual Meeting
June 13, 2025
·
5 min read
Clinical research
Undeterred by Political, Economic Headwinds, Pharma Ups R&D Investment in 2024 and Beyond
R&D spending across the global pharmaceutical sector climbed 1.5% in 2024, according to unreleased data from Evaluate Pharma.
May 28, 2025
·
12 min read
·
Tristan Manalac
Tariffs
Trump Opens National Security Probe on Pharma Imports, Signaling Imminent Tariffs
Trump could use the findings of the probe to impose certain trade restrictions on pharma products, including tariffs.
April 15, 2025
·
2 min read
·
Tristan Manalac
FDA
Tris Pharma Gets FDA Approval for Non-Stimulant ADHD Medication
Tris Pharma on Wednesday secured the FDA’s green light for Onyda XR, the first liquid non-stimulant nighttime treatment for attention deficit hyperactivity disorder in pediatric patients.
May 30, 2024
·
1 min read
·
Tristan Manalac
Business
Five Biggest Drug Face-Offs in Pharma History
Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of rivalry that includes blockbuster drugs Keytruda, Humira and Eliquis.
April 9, 2025
·
9 min read
·
Tristan Manalac
Pharm Country
Tris Pharma Launches Digital Health Business to Develop and Commercialize Digital Products for ADHD
Tris Pharma, Inc. has entered into a licensing agreement with Braingaze Ltd. and launched its new business, Tris Digital Health, which will focus on the development and commercialization of digital diagnostic and therapeutic products for neurological health conditions.
April 16, 2024
·
5 min read
Pain
Tris Pharma Records Late-Stage Win for Non-Opioid Painkiller
Cebranopadol, a dual-NMR agonist, reached the primary endpoint in a Phase III trial and matched placebo for safety, a significant concern in the analgesic field.
January 22, 2025
·
1 min read
·
Dan Samorodnitsky
Press Releases
Tris Pharma to Present New Data at AAPM PainConnect Annual Meeting and Showcase Potential of Cebranopadol, a First-in-Class Investigational Dual-NMR Agonist for the Treatment of Pain
April 1, 2025
·
5 min read
Government
Trump Tariffs Miss Pharma For Now, But Uncertainties Loom
Pharma’s reprieve from Donald Trump’s tariffs is expected to be temporary, with Leerink analysts anticipating possible sector-specific duties “in the next month or so.”
April 3, 2025
·
2 min read
·
Tristan Manalac
1 of 73,200
Next
